Somewhat Favorable News Coverage Somewhat Unlikely to Impact Teva Pharmaceutical Industries (TEVA) Share Price
News coverage about Teva Pharmaceutical Industries (NYSE:TEVA) has been trending somewhat positive on Saturday, Accern Sentiment reports. Accern ranks the sentiment of news coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Teva Pharmaceutical Industries earned a media sentiment score of 0.15 on Accern’s scale. Accern also gave news coverage about the company an impact score of 46.1085838846995 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the near future.
Here are some of the news articles that may have effected Accern Sentiment’s analysis:
- Berkshire’s 4th Quarter Buy Teva Appears Cheap and Troubled (finance.yahoo.com)
- Is Teva A Falling Drug Company Or A Great Value Proposition – Seeking Alpha (seekingalpha.com)
- Early Moves to Watch – Teva Pharmaceutical Industries Limited (NYSE: TEVA) – Alpha Beta Stock (alphabetastock.com)
- Healthcare: Warren Buffett's Surprising New Buy (finance.yahoo.com)
- Teva's Problems Continue to Mount With No Relief in Sight (finance.yahoo.com)
Teva Pharmaceutical Industries (TEVA) traded up $0.24 on Friday, hitting $20.04. 7,270,000 shares of the stock were exchanged, compared to its average volume of 20,640,000. Teva Pharmaceutical Industries has a one year low of $10.85 and a one year high of $35.91. The company has a current ratio of 0.86, a quick ratio of 0.58 and a debt-to-equity ratio of 1.91. The firm has a market cap of $20,380.00, a P/E ratio of -1.16, a P/E/G ratio of 1.72 and a beta of 0.59.
A number of equities analysts recently commented on the stock. ValuEngine raised shares of Teva Pharmaceutical Industries from a “hold” rating to a “buy” rating in a research report on Thursday, February 15th. Wells Fargo & Co reissued a “sell” rating on shares of Teva Pharmaceutical Industries in a report on Tuesday, February 13th. Credit Suisse Group raised shares of Teva Pharmaceutical Industries from a “neutral” rating to an “outperform” rating and raised their target price for the company from $20.00 to $23.00 in a report on Sunday, February 11th. Bank of America decreased their target price on shares of Teva Pharmaceutical Industries from $17.00 to $16.00 and set an “underperform” rating on the stock in a report on Friday, February 9th. Finally, Leerink Swann decreased their target price on shares of Teva Pharmaceutical Industries from $17.00 to $16.00 and set an “underperform” rating on the stock in a report on Friday, February 9th. Ten investment analysts have rated the stock with a sell rating, fifteen have issued a hold rating and eight have given a buy rating to the stock. The company presently has an average rating of “Hold” and an average price target of $21.26.
In related news, EVP Mark Sabag sold 5,050 shares of Teva Pharmaceutical Industries stock in a transaction that occurred on Thursday, February 15th. The shares were sold at an average price of $19.68, for a total transaction of $99,384.00. Following the sale, the executive vice president now directly owns 44,517 shares in the company, valued at approximately $876,094.56. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. 7.10% of the stock is owned by company insiders.
Teva Pharmaceutical Industries Company Profile
Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.
Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.